349

350

REFERENCES

1. Kevin A. Cassady, Helen Yun, Clinical Pathology Made Ridiculously

Simple, 2001

2. P.N. Bennett, M.J. Brown, Clinical Pharmacology, Churchill

Livingstone Publications, 2003.

3. Knox Van Dyke ,Karen Woodfork, Modern Pharmacology and Clinical

Applications, 2002.

4. Goodman & Gilman's The Pharmacological Basis of Therapeutics -

11th Ed. 2006.

5. Greene, W.C., and Peterlin, B.M. Charting HIV's remarkable voyage

through the cell: Basic science as a passport to future therapy. Nature

Med., 2002, 8:673-680. Pubmed

6. Christine M, Pharmacology for the Health Care Professions, 2008.

7. James B. Chin, Control of Communicable Diseases Manual, APHA,

2000.

8. UNAIDS, Report on the Global HIV/AIDS Epidemic. UNAIDS2006

9. Rambaut A, Posada D, Crandall KA, Holmes EC, The causes and

consequences of HIV evolution. Nat. Rev.Genet, 2004, 5, 52–61.

10. 10. Hu W S, Rhodes Q D, V. Pathak, Retroviral recombination: review

of genetic analyses, Front.Biosci, 2003, 8, 143–155

11. Najera R, Delgado E,. Perez A L, Thomson M M, Genetic recombination

and its role in the development of the HIV-1 pandemic, AIDS, 2002,

16:S3-S16.

12. Najera R, Delgado E,. Perez A L, Thomson M M, Genetic recombination and

its role in the development of the HIV-1 pandemic, AIDS, 2002, 16:S3-S16

351

13. Thomson M M, Najera R, Delgado E, Perez A L, Molecular epidemiology of

HIV-1 genetic forms and its significance for vaccine development and

therapy, Lancet Infect. Dis. 2002, 2,461–471

14. Chen LF, Hoy J, Lewin SR Ten years of highly active antiretroviral therapy

for HIV infection. Med. J. Aust. 2007, 186, 146–151

15. Simon V, Ho D D, Abdool K Q, HIV/AIDS epidemiology, pathogenesis

prevention and treatment. Lancet , 2006, 368, 489–504

16. Lassen K, The multi factorial nature of HIV-1 latency, Trends Mol. Med,

2004, 10, 525–531

17. Marcello A L, The hidden HIV-1 challenge. Retrovirology, 2006, 3, 7

18. Richman D D, Antiviral drug resistance. Antiviral Res. 2006, 71, 117–121

19. Xiaoling L, William K C, Transport, metabolism and elimination mechanisms

of anti-HIV agents, Adv. Drug,Del. Rev, 1999, 39, 81.

20. Bruce J A, P-glycoprotein secretory transport, and other barriers to the oral

delivery of anti-HIV drugs, Adv. Drug. Del. Rev., 1999, 39,105

21. Dae D K, Chien Y W, Simultaneous skin permeation of dideoxynucleoside-

type anti-HIV drugs J. Control. Rel, 1996, 40, 67.

22. Dae D K, Chien Y W, Comparison of Skin Permeation of Dideoxynucleoside-

Type Anti-HIV Drugs: Alone Versus Combination, Drug Develop. Ind. Pharm,

1996, 22,1047.

23. Yi J, Toshinobu S, Yasunori M, Kazuhiko J, Effect of Application

Volume of Ethanol-Isopropyl Myristate Mixed Solvent System on

Permeation of Zidovudine and Probenecid Through Rat Skin, Drug

352

Develop Ind. Pharm, 2000, 26, 193.

24. Thomas N S, Panchagnula R, Transdermal delivery of zidovudine:

effect of vehicles on permeation across rat skin and their mechanism

of action Eur. J. Pharm. Sci, 2003, 18, 71.

25. Oussoren C, Magnani M, Fraternale A, Casabianca A, Chiarantini L,

Ingebrigsten R., Underberg W J, Storm G, Liposomes as carriers of the

antiretroviral agent dideoxycytidine-5′-triphosphate Int. J. Pharm, 1999,

180, 261.

26. Duzgunes N, Pretzer E, Simoes S, Slepushkin V, Konopka K, Flasher D ,

Lima M C, Liposome-mediated delivery of antiviral agents to human

immunodeficiency virus-infected cells Mol. Membrane Biol, 1999, 16, 111.

27. Jun Chena, William E. Blevinsb, Haesun Parkc, Kinam Park, Gastric

Retention Properties of Superporous Hydrogel Composites, Journal of

Controlled Release, 64 (2000) 39–51

28. Feleke F, Aendale T , Gebre C, Oral floating extended release

stavudine hydrophilic matrix tablets: formulation design and in vitro

investigations, Ethiopian Pharmaceutical Journal , 2007, 25 , 51-62.

29. Robert D, Denise M J, Sustained release beadlets containing stavudine, US

patent 7135465, 2001.

30. Sahoo S, Mallick A A, Barik B B, Senapathi P C, Formulation and in vitro

Evaluation of Eudragit Microspheres of Stavudine, Tropical Journal of

Pharmaceutical Research, 2005, 4, 369-375,

31. Sureshwar P, Poly (lactide-co-glycolide) microspheres of stavudine were

prepared by the solvent evaporation technique, IPC 2008

32. U.S. Department of Health and Human Services, Food and Drug

Administration,Center for Drug Evaluation and Research (CDER),

353

Drugs@FDA, Zerit XR, stavudine,label, 2008

33. Ravi P R, Ganga S, Saha R N, Design and Study of Lamivudine Oral

Controlled Release Tablets, AAPS PharmSciTech, 2007, 8 , 167-175,.

34. Himadri sen, Surva Kumar J, inventors. Long acting composition containing

zidovudine and Lamivudine. US patent publication US 20050175694A1.

August 11, 2005.

35. Amitava Ghosh, Udaya Kumar Nayak, Partha Roy, Development, evaluation

and method selection for the preparation of lamivudine microspheres,

Pharmacy on-line, 2007.

36. Prathiba V , Bharathi A, Formulation & evaluation of lamivudine

microspheres, Pharmabiz, August 2008.

37. Ingunn Tho , Bernd Liepold, Joerg Rosenberg, Markus Maegerlein, Martin Brandl and Gert Fricker

Formation of nano/micro-dispersions with improved dissolution

properties upon dispersion of ritonavir melt extrudate in aqueous

media‖ EuropeanJournalofPharmaceuticalSciences Volume 40, Issue

1, 16 April 2010, Pages 25-32.

38. Manuela Ehrhardt0, Marion Möck, Walter E. Haefeli, Gerd Mikus and

Jürgen Burhenne ―Monitoring of lopinavir and ritonavir in peripheral

blood mononuclear cells, plasma, and ultrafiltrate using a selective

and highly sensitive LC/MS/MS assay‖ JournalofChromatograph

Volume 850, Issues 1-2, 1 May 2007, Pages 249-258.

39. John Ray, Edna Pang and Dianne Carey ―Simultaneous determination

of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by

high-performance liquid chromatography‖ JournalofChromatography

Volume 775, Issue 2, 5 August 2002, Pages 225-230.

40. Eliane Maria Donato, Laura Alegria Martins, Pedro Eduardo Fröehlich,

354

and Ana Maria Bergold Development and validation of dissolution test

for lopinavir, a poorly water-soluble drug, in soft gel capsules, based

on in vivo data‖ JournalofPharmaceuticalandBiomedicalAnalysis

Volume 47, Issue 3, 15 July 2008, Pages 547-552 .

41. Yan Shen 1 and Jiasheng Tu Preparaed and evaluated the Ocular

Pharmacokinetics of Ganciclovir Liposomes. Int. J. Pharm., 2008,

195(1-2), 125-135.

42. Rahman Z, Ali M, Khar RK. Design and evaluation of bilayer floating

tablets of captopril. Acta Pharm.2006; 56: 49-57.

43. Xiaoqiang Xu, Minije S, Feng Z, Yiqiao Hu. Floating matrix dosage

form for phenoporlamine hydrochloride based on gas forming agent: In

vitro and in vivo evaluation in healthy volunteers. Int J Pharm. 2006;

310:139-145.

44. Srivastava AK, Ridhurkar DN, Wadhwa S. Floating microspheres of

cimetidine: formulation, characterization and in vitro evaluation. Acta.

Pharm. 2005; 55: 277-285.

45. Jain SK, Awasthi AM, Jain NK, Agarwal GP. Calcium silicate based

microspheres of repaglinide for gastroretentive floating drug delivery:

preparation and in vitro characterization. J. Control. Release. 2005;

107: 300-309.

46. El-Kamel AH, Sokar MS, AlGamal SS, Naggar VF. Preparation and

evaluation of ketoprofen floating oral drug delivery system. Int. J.

Pharm. 2001; 220:13-21.

47. Mine O., Evren H, G., Gokhan E., 2006 Release and diffusional

modeling of metronidazole matrices.Eur.J.Pharm.Biopharm.,63, 331-

339.

48. Feng-Quian L., et al., 2006, In-vitro controlled release of sodium

ferulate from compritol 888 ATO- based matrix tablets.Int J

355

.Pharm.,324, 152-157.

49. Testuo H., et al., 2005. Formulation study and drug release

mechanism of a new theophylline sustained release prepration. Int. J.

Pharm., 304, 91-101.

50. Yu-E-Zhang, Joseph B.S., 2003. Melt granulation and heat treatment

for wax matrix-controlled release. Drug. dev. Ind. Pharm., 29(2), 131-

138.

51. Aiman A.O2001.controlled release of Tramadol hydrochloride from

matrices prepared using glyceryl Behenate. Eur. j. pharm. Biopharm.,

52, 231-235.

52. Alan, 1996.alternative granulation technique: Melt granulation. Drug.

Dev. ind. pharm., 29(9), 917-924.

53. Parish, Edward J.; Terrence L. Boos; Shengrong Li (2002). "The

Chemistry of Waxes and Sterols". in Casimir C. Akoh, David B. Min..

Food lipids: chemistry, nutrition, and biochemistry (2nd ed.). New

York: M. Dekker. p. 103. ISBN 0824707494.

54. Dave BS, Amin AF, Patel MM. Gastroretentive Drug Delivery System of

Ranitidine hydrochloride: formulation and invitro evaluation. AAPS

Pharm. Sci. Tech. 2004; 5(2): article 34.

55. Yang, L., Esharghi, J., Fassihi, R., ―A new intra gastric delivery system

for the treatment of helicobacter pylori associated gastric ulcers: in

vitro evaluation‖, J Control. Rel., 1999, 57(3), 215-222.

56. Wu, W., Zhou, Q., Zhang, H.B., Ma, G.D., Fu, C.D., ―Studies on

nimodipine sustained release tablet capable of floating on gastric

fluids with prolonged gastric resident time‖, Yao. Xue. Xue. Bao.,

1997, 32 (10), 786-790.

57. Xiaoqiang, X., Minjie, S., Feng, Z., Yiqiao, H., ―Floating matrix dosage

356

form for phenoporlamine hydrochloride based on gas forming agent: In

vitro and in vivo evaluation in healthy volunteers‖, Int. J. Pharm.,

2006, 310(1-2), 139-145.

58. Shoufeng L, Senshang L, Chein YW,Daggy BP, Mirchandani HL.

Statisticaloptimization of gastric gloating systemfor oral controlled

delivery of calcium.AAPS Pharm. Sci. Tech. 2001; 2: 1‐12.

59. Deshpande AA, Shah NH, Rhodes CT,Malick W. Development of a

novelcontrolled release system for gastricretention. Pharm. Res. 1997;

14(6):815‐819.

60. Margret chandira, debjit bhowmik, chiranjib, b. jayakar formulation

and evaluation of gastroretentive drug deliverysystem of

gastroprokinetic drug itopride hydrochloride International Journal of

Pharmacy and Pharmaceutical Sciences Vol 2, Issue 1, 2010.

61. El‐Kamel, Sokas MS, Algamal SS.Preparation and evaluation

ofKetoprofen floating oral delivery system. Int. J. Pharm. 2001; 220 :

13‐21.

62. Chinam niranjan patra et al, Design and evaluation of sustained

release bilayer tablets of propranolol hydrochloride Acta Pharm. 57

(2007) 479–48910.2478/v10007-007-0038-0.

63. Eunice K K, Cristina H R, Eunice E M, Simone S A, Valentina P,

Determination of lamivudine in human plasma by HPLC and its use in

bioequivalence studies, International Journal of Pharmaceutics 2005, 297,

73–79.

64. Namita K, Sateesh K, Ramesh P, Simultaneous determination of lamivudine

and stavudine in antiretroviral fixed dose combinations by first derivative

spectrophotometry and high performance liquid chromatography, Journal of

Pharmaceutical and Biomedical Analysis 2006, 41, 761–765.

357

65. Bin Fan, James T. Stewart, Determination of zidovudine

/lamivudine/nevirapine in human plasma using ion-pair HPLC, Journal of

Pharmaceutical and Biomedical Analysis 2002, 28 , 903–908.

66. Emilia Marchei , Luisa Valvo , Roberta Pacifici, Manuela Pellegrini ,Gianna

Tossini , Piergiorgio Zuccaro , Simultaneous determination of zidovudine and

nevirapine in human plasma by RP-LC, Journal of Pharmaceutical and

Biomedical Analysis, 2002, 29 ,1081–1088.

67. Ashenafi Dunge, Nishi Sharda, Baljinder Singh, Saranjit Singh, Validated

specific HPLC method for determination of zidovudine during stability

studies, Journal of Pharmaceutical and Biomedical Analysis ,2005, 37 ()

1109–1114.

68. C. M. Phechkrajang, E.E. Thin, L. Sratthaphut, D. Nacapricha and P.

Wilairat ―Quantitative Determination of Lopinavir and Ritonavir in

Syrup Preparation by Liquid Chromatography‖ Mahidol University

Journal of Pharmaceutical Science 2009; 36 (1-4), 1-12.

69. Usami Y, Oki T, Nakai M, Sagisaka M, Kaneda T. ―A simple HPLC

method for simultaneous determination of lopinavir, ritonavir and

efavirenz‖ Chem Pharm Bull (Tokyo). 2003 Jun; 51(6):715-8.

70. U.S. Department of Health and Human Services, Food and Drug

Administration,Center for Drug Evaluation and Research (CDER),

Drugs@FDA, Retrovir, zidovudine, Label information, 2007.

71. U.S. Department of Health and Human Services, Food and Drug

administration,Center for Drug Evaluation and Research (CDER),

Drugs@FDA, Epivir, lamivudine, Label information, 2008.

72. U.S. Department of Health and Human Services, Food and Drug

Administration,Center for Drug Evaluation and Research (CDER),

Drugs@FDA, Retrovir, zidovudine, Label information, 2009.

358

73. U.S. Department of Health and Human Services, Food and Drug

Administration,Center for Drug Evaluation and Research (CDER),

Drugs@FDA, Retrovir, zidovudine, Label information, 2009.

74. U.S. Department of Health and Human Services, Food and Drug

Administration,Center for Drug Evaluation and Research (CDER),

Drugs@FDA, Retrovir, zidovudine, Label information, 2010.

75. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 556-561.

76. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 286-288.

77. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 293-294.

78. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 762-763.

79. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 542-549.

80. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 772-774.

81. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 290-293.

82. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 554-556.

83. http://www.gattefosse.com/media/document/tds_sedefos_75.pdf,

Pg-1-3.

84. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 517-522.

359

85. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 525-533.

86. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 317-325.

87. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 317-325.

88. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 317-325.

89. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg517-520.

90. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg517-520.

91. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg110-114.

92. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 622-624.

93. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 404-408.

94. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row

Pharmaceutical Press, London, 2009. Pg 129-131.

95. Hilton Ak, Deasy PB. In vitro and in vivo evaluation of an oral

sustained release floating dosage form of amoxicillin trihydrate. Int. J.

Pharm. 1992; 86:79-88.

96. Shyam Shimpi, Bhaskar Chauhan, K. R. Mahadik, and Anant

Paradkar. Preparation and Evaluation of Diltiazem Hydrochloride-

Gelucire 43/01 Floating Granules Prepared by Melt Granulation. AAPS

360

PharmSciTech 2004; 5 (3).

97. Bhaskar Chauhan, Shyam shimpi, K.R. Mahadik. Preparation and

Evaluation of Floating Risedronate Sodium-Gelucire 43/01

Formulations. Drug. Dev -Ind-Pharm31: 851-860, 2005.

98. Arthur H K, Hand book of pharmaceutical excepients, 3 rd ed,

American pharmaceutical association, Washington DC, 2000,

Appendix II, 642.

99. Shyam shimpi, K.R. Mahadik. Drug. Dev -Ind-Pharm31: 701-10,

2004.

100 S. J. Hwang, H. Park, K.Park,―Gastric retentive drug delivery systems.‖

Crit. Rev. Ther. Drug Carrier Syst., 1998.15, 243–284.

101. ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and

Products, http://www.emea.europa.eu

102. Lazarus, J. and Cooper, J., J. Pharm. Sci., 50, 715, 1961.

103. Wagner, J.G., J. Pharm. Sci., 58, 1253, 1969.

104. Higuchi, T., J. Pharm. Sci., 52, 1145, 1963.

105. Korsemeyer, E. W., Gurny, R., Doelker, E.M., Buri, p. and Peppas,

N.A., Int, J. Pharm., 21, 25, 1983.

106. Ritger, P.L and Peppas, N.A., J. Control. Release, 5, 37, 1987.

107. Food & Drug Administration, SUPAC-IR Questions and Answers.

Center for Drug Evaluation and Research, 1995.

108. Food & Drug Administration, Guidance for Industry: Dissolution

Testing of Immediate Release Solid Dosage Forms. Center for Drug

Evaluation and Research, 1997.

109. Food & Drug Administration (a) In: Guidance for Industry: Immediate

361

Release Solid Dosage Forms: Scale-up and Post Approval Changes

(SUPAC-IR): Chemistry, Manufacturing and Controls, In Vitro

Dissolution Testing and In Vivo Bioequivalence Documentation. Center

for Drug Evaluation and Research, 1995.

110. Bhaskar Chauhan, Shyam shimpi, K.R. Mahadik. Preparation and

Evaluation of Floating Risedronate Sodium-Gelucire 43/01

Formulations. Drug. Dev -Ind-Pharm31: 851-860, 2005.

111. Shyam Shimpi, Bhaskar Chauhan, K. R. Mahadik, and Anant

Paradkar. Preparation and Evaluation of Diltiazem Hydrochloride-

Gelucire 43/01 Floating Granules Prepared by Melt Granulation. AAPS

PharmSciTech 2004; 5 (3).

112. Basak SC, NagashwaraRao K, Manavalan R,RamaRao P. Indian

J..Pharm. Sci. 2006; 66(3): 313-316.

113. Talukder R, Fassihi R, Jain NK. A new approach in gastro retentive

delivery systems Drug. Dev -Ind-Pharm; 30(4): 405-412.

114. Arthur H K, Hand book of pharmaceutical excepients, 3 rd ed,

American pharmaceutical association, Washington DC, 2000,

Appendix II, 642.

115. Food & Drug Administration, SUPAC-IR Questions and

Answers.Center for Drug Evaluation and Research, 1995.

116. Shyam Shimpi, Bhaskar Chauhan, K. R. Mahadik, and Anant

Paradkar. Preparation and Evaluation of Diltiazem Hydrochloride-

Gelucire 43/01 Floating Granules Prepared by Melt Granulation. AAPS

PharmSciTech 2004; 5 (3).

117. ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and

Products, http://www.emea.europa.eu.

118. Food & Drug Administration, Guidance for Industry: Dissolution

362

Testing of Immediate Release Solid Dosage Forms. Center for Drug

Evaluation and Research,1997

119. Food & Drug Administration, Guidance for Industry: Immediate

Release Solid Dosage Forms: Scale-up and Post Approval Changes

(SUPAC-IR): Chemistry, Manufacturing and Controls, In Vitro

Dissolution Testing and In Vivo Bioequivalence Documentation. Center

for Drug Evaluation and Research. 1995.

120. Ansal H C, Popovich N G, Allen L V. Jr. Pharmaceutical Dosage forms

and Drug Delivery Systems, , B.I Waverly, 6 th Ed ,

Newdelhi,1999,61.

121. Cuny L D, Huwyler J, Wiese M, Kansy M, Computational aqueous

solubility prediction for drug-like compounds in congeneric series

European Journal of Medicinal Chemistry, 2008, 43, 501.

122. Lipinski C A, Lombardo F, Dominy B W, Feeney PJ, Experimental and

computational approaches to estimate solubility and permeability in

drug discovery and development settings, Adv. Drug Delivery. Reviews,

2001, 46, 3.

123. S K Sahoo, Abdul A M, BB Barik, Prakash , Formulation and in vitro

Evaluation of Eudragit Microspheres of Stavudine, Tropical Journal of

Pharmaceutical Research, 2005; 4 , 369-375.

124. Punna R Ri, Sindhura G, and Ranendra N S, Design and Study of

Lamivudine Oral Controlled Release Tablets, AAPS PharmSciTech,

2007, 8, 4.

125. D.Varun, Bahul Z Awen, Ch. Babu Rao, K.Mukkanti and P.Nagaraju,

A Validated Reverse Phase HPLC method for the Simultaneous

Estimation of Ritonavir and Lopinavir in Pharmaceutical Dosage

Forms, Asian J. Research Chem. 3(3): July- Sept. 2010, 805-808.

363

126. Varun Dasari, Babu Rao Chandu, Mukkanti Khagga, Sumalatha

Gindi, New Simple UV Spectrophotometric Method For the Estimation

of Valganciclovir In Bulk And Its Formulation, Pharmanest, An

International Journal of Advances in Pharmaceutical Sciences, 2010,

Nov-Dec, 1(2), 282-286.

127. V.Lannuccelli, G.Coppi, R. Sansone And G. Ferolla, Air Compartment

Multiunit System For Prolonged Gastric Residence, part II- In vivo

Evaluation, Int.J. Pharma, 1982, 174 (1-2), 55-62.

128. I.R. Wiliding and S.P. Newmman, Ginving Decissions More Precious In

Drug Development, Use of Radionuclide Imaging, Drug. Dev. Syst. &

Scie, 2001, 1(1), 5-10.

129. Shah SH, Patel JK, Patel NV. Stomach specific floating drug delivery

system: A Review, Int. J. Pharm. Res. CODEN (USA): IJPRIF ISSN:

0974‐4304.2009; 3:623‐633.